ORPHA:219
Delta-sarcoglycan-related limb-girdle muscular dystrophy R6
Also known as: Limb-girdle muscular dystrophy due to delta-sarcoglycan deficiency · Limb-girdle muscular dystrophy type 2F · Autosomal recessive limb-girdle muscular dystrophy type 2F · Delta-sarcoglycan-related LGMD R6 · Delta-sarcoglycanopathy · LGMD due to delta-sarcoglycan deficiency · LGMD type 2F · LGMD2F
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
207
59.5th percentile
Trials
0
Interventional, condition-specific
Researchers
1,127
Distinct authors in sample
Gene link
SGCD
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A subtype of limb-girdle muscular characterized by a variable age of onset of weakness and wasting of the proximal skeletal muscles of the shoulder and pelvic girdles, frequently associated with respiratory muscle impairment and . Calf hypertrophy, muscle cramps and elevated serum creatine kinase levels are also observed. Neuropsychomotor development is usually normal.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011028
- MeSH:C535896
- OMIM:601287
- UMLS:C1832525
Additional Mondo synonyms (4)
SGCD autosomal recessive limb-girdle muscular dystrophy · autosomal recessive limb-girdle muscular dystrophy caused by mutation in SGCD · limb-girdle muscular dystrophy due to delta-sarcoglycan deficiency · muscular dystrophy, limb-girdle, autosomal recessive 6
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Definitive — SGCD
- LiteraturePresent
207 matched papers (68 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 24 for broader category limb-girdle muscular dystrophy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (SGCD).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
207
207 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
207 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
68 in the last 10 years · high confidence · 59.5th percentile (publications denominator)
Phrase hits: 207 · MeSH hits: 0
Who's working on it?
1,127
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Straub V14 papers · 2026
Institute of Human Genetics, University of Newcastle upon Tyne, United Kingdom. volker.straub@ncl.ac.uk
Papers in Europe PMC - 02Nigro V12 papers · 2014
Dipartimento di Patologia Generale e Centro di Eccellenza sulle Malattie Cardiovascolari, Seconda Università degli Studi di Napoli, Telethon Institute of Genetics and Medicine (TIGEM), Napoli, Italy. vincenzo.nigro@unina2.it
Papers in Europe PMC - 03Zatz M12 papers · 2016
Human Genome and Research Center (HUG-CELL), Instituto de Biociências, Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Papers in Europe PMC - 04
- 05Angelini C10 papers · 2025
IRCCS Fondazione "San Camillo" Hospital, Lido di Venezia, Italy;
Papers in Europe PMC - 06Passos-Bueno MR9 papers · 2016
Departamento de Biologia, Instituto de Biociências, São Paulo, Brazil.
Papers in Europe PMC - 07McNally EM8 papers · 2024
Department of Medicine, University of Chicago, Chicago, Illinois 60637.
Papers in Europe PMC - 08Nigro G8 papers · 2016
Arrhythmologic Unit, Department of Cardiology. University of Campania "Luigi Vanvitelli", Naples, Italy.
Papers in Europe PMC - 09Beckmann JS7 papers · 2024
Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland.
Papers in Europe PMC - 10Campbell KP7 papers · 2025
Howard Hughes Medical Institute, Department of Molecular Physiology and Biophysics, Department of Neurology, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, 4283 Carver Biomedical Research Building, 285 Newton Road, Iowa City, Iowa, 52242-1101, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial. 24 trials are registered for limb-girdle muscular dystrophy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
24 interventional trials matched limb-girdle muscular dystrophy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: limb-girdle muscular dystrophy
24
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07711730·RECRUITING·Telecare Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy
Conditions: Limb-Girdle Muscular Dystrophy · Social Competence · Self Esteem · Health Related Quality of Life·Matched via name phrase
- NCT05230459·RECRUITING·A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Conditions: Limb Girdle Muscular Dystrophy · Limb-Girdle Muscular Dystrophy Type 2 · LGMD2I · Muscular Dystrophy·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05989620·RECRUITING·Long-Term Development of Muscular Dystrophy Outcome Assessments
Conditions: LGMD1B · LGMD1C · LGMD1D · LGMD1E·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Delta-sarcoglycan-related limb-girdle muscular dystrophy R6" OR "Limb-girdle muscular dystrophy due to delta-sarcoglycan deficiency" OR "Limb-girdle muscular dystrophy type 2F" OR "Autosomal recessive limb-girdle muscular dystrophy type 2F" OR "Delta-sarcoglycan-related LGMD R6" OR "Delta-sarcoglycanopathy" OR "LGMD due to delta-sarcoglycan deficiency" OR "LGMD type 2F" OR "LGMD2F" OR "SGCD autosomal recessive limb-girdle muscular dystrophy" OR "autosomal recessive limb-girdle muscular dystrophy caused by mutation in SGCD" OR "muscular dystrophy, limb-girdle, autosomal recessive 6"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Delta-sarcoglycan-related limb-girdle muscular dystrophy R6" OR "Limb-girdle muscular dystrophy due to delta-sarcoglycan deficiency" OR "Limb-girdle muscular dystrophy type 2F" OR "Autosomal recessive limb-girdle muscular dystrophy type 2F" OR "Delta-sarcoglycan-related LGMD R6" OR "Delta-sarcoglycanopathy" OR "LGMD due to delta-sarcoglycan deficiency" OR "LGMD type 2F" OR "LGMD2F" OR "SGCD autosomal recessive limb-girdle muscular dystrophy" OR "autosomal recessive limb-girdle muscular dystrophy caused by mutation in SGCD" OR "muscular dystrophy, limb-girdle, autosomal recessive 6" OR "SGCD" OR "autosomal recessive limb-girdle muscular dystrophy" OR "qualitative or quantitative defects of delta-sarcoglycan"
Recall-expansion terms: SGCD, autosomal recessive limb-girdle muscular dystrophy, qualitative or quantitative defects of delta-sarcoglycan
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"limb-girdle muscular dystrophy"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T12:56:35.243Z